SCHEMBL5224912

SCHEMBL5224912

CC(C)(C)OC(=O)N1CCN2C(=O)CC(=O)C2(Cc2ccc(F)cc2)C1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.42
GPR119 Q8TDV5 1/20 0.42
RORC P51449 4/20 0.41
F2RL1 P55085 2/20 0.40
HDAC2 Q92769 2/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
IDO2 Q6ZQW0 1/20 0.39
DNMT3A Q9Y6K1 1/20 0.38
HDAC1 Q13547 1/20 0.37
GRIA1 P42261 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
P2RX7 Q99572 1/20 0.37
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6697164 0.90 KDM1A (0.43) KDM1AGPR119RORCF2RL1HDAC2
SCHEMBL5229477 0.83 GPR119 (0.42) KDM1AGPR119RORCF2RL1HDAC2
SCHEMBL6694182 0.82 KDM1A (0.44) KDM1AGPR119RORCF2RL1HDAC2
SCHEMBL6690501 0.81 KDM1A (0.41) KDM1AGPR119RORCF2RL1HDAC2
SCHEMBL6691130 0.81 DNMT3A (0.41) KDM1AGPR119RORCF2RL1HDAC2
SCHEMBL6692315 0.80 CNR1 (0.39) KDM1AGPR119RORCF2RL1HDAC2
SCHEMBL6698251 0.80 KDM1A (0.39) KDM1AGPR119RORCF2RL1HDAC2
SCHEMBL5224568 0.78 GPR119 (0.42) GPR119
SCHEMBL22397199 0.73 CNR1 (0.44) KDM1ARORCHDAC2CNR1CNR2
SCHEMBL21199085 0.73 CNR1 (0.44) KDM1ARORCHDAC2CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1001970-B1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER (US) 2007-03-07 EP disclosed
US-6953791-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-11 US disclosed
US-6951850-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-04 US disclosed
US-6924280-B2 Dipeptide derivatives PFIZER INC. (US) 2005-08-02 US disclosed
EP-1002802-B1 Dipeptide derivatives as growth hormone secretagogues PFIZER PROD INC (US) 2004-12-08 EP disclosed
US-RE38524-E1 Dipeptide derivatives as growth hormone secretagogues PFIZER INC. 2004-06-01 US disclosed
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure CARPINO PHILIP ALBERT (US) 2004-01-15 US disclosed
US-20040006063-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2004-01-08 US disclosed
US-20030216399-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2003-11-20 US disclosed
US-6525047-B2 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair PFIZER INC. 2003-02-25 US disclosed
US-6433171-B1 FOR OSTEOPOROSIS AND/OR FRAILTY, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ATTENUATING PROTEIN CATABOLIC RESPONSE AFTER A MAJOR OPERATION, REDUCING CACHEXIA AND PROTEIN LOSS PFIZER INC. 2002-08-13 US disclosed
US-6432945-B1 Dipeptide derivatives PFIZER INC. 2002-08-13 US disclosed
US-20010041703-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2001-11-15 US disclosed
US-6251902-B1 Dipeptide derivatives as growth hormone secretagogues PFIZER INC. 2001-06-26 US disclosed
US-6194578-B1 GROWTH HORMONE SECRETAGOGUES; USEFUL FOR PROPHYLAXIS AND THERAPY OF OSTEOPOROSIS AND/OR FRAILTY, INSULIN RESISTANCE IN MAMMALS, CONGESTIVE HEART FAILURE, OBESITY, ACCELERATING BONE FRACTURE REPAIR REDUCING CACHEXIA AND PROTEIN LOSS PFIZER INC. 2001-02-27 US disclosed
EP-1002802-A1 Dipeptide derivatives as growth hormone secretagogues Pfizer Products Inc. (US) 2000-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure GHSR, GHRHR, GIPR KDM1A 4452/4885GPR119 59/4885RORC 3587/4885
US-20010041703-A1 Dipeptide derivatives GIPR, GHRHR, GHSR KDM1A 4522/4885GPR119 55/4885RORC 4146/4885
US-20040006063-A1 Dipeptide derivatives GIPR, GHRHR, GHSR KDM1A 4258/4885GPR119 40/4885RORC 4236/4885
US-20030216399-A1 Dipeptide derivatives GIPR, GHRHR, GHSR KDM1A 4542/4885GPR119 53/4885RORC 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.